Abstracts / Contact Lens & Anterior Eye 38 (2015) e13–e46
comfortable wear and having Class I UV blocking capability, were developed. Dr. Yu-Chin Lai, Vice President of R&D, Pegavision Corporation in Taiwan. Before joining Pegavision, he had 23 years of career with Bausch & Lomb working on new contact lens materials, IOL’s and processing. He was credited with the inventions of Soflens66, Soflens59 and the successful development of PureVision. He received his doctoral degree in chemistry from University of Florida. He was granted 79 US patents, mostly related to lens materials and processing. He received Industrial Innovation Award from American Chemical Society in 2004. He has over 60 scientific publications, over 70 professional presentations and invited talks. http://dx.doi.org/10.1016/j.clae.2014.11.016 16 Discrimination of ocular discomfort between contact lenses Percy Lazon de la Jara 1 , Thomas Naduvilath 2 , Jennie Diec 2 , Brien Holden 3 , Eric Papas 3 1 Brien Holden Vision Institute and School of Optometry and Vision Science, University of New South Wales, Sydney, Australia 2 Brien Holden Vision Institute, Level 5, North Wing, RMB, Gate 14, Barker Street, University of New South Wales, Sydney, NSW 2052, Australia 3 Vision Cooperative Research Centre, Level 5, North Wing, RMB, Gate 14, Barker Street, University of New South Wales, Sydney, NSW 2052, Australia
Purpose: To develop a contact lens discomfort scale that successfully discriminates discomfort between contact lens (CL) types. Method: Forty experienced clinical trial participants took part in focus groups to investigate their perceptions of various ocular comfort scales. From these responses a ranked symptoms-discomfort (RSD) scale was developed. For further evaluation, 20 CL wearers were enrolled into a prospective, randomised, crossover clinical trial. Two CL (SiHy A & SiHy B) and one solution combination were randomly allocated across two stages of 14 days. The RSD scale and a traditional comfort (TC) scale were administered on alternating days, after CL insertion and prior to CL removal. For the TC scale, participants rated their ocular comfort on a 1–10 scale (1 = poor & 10 = excellent). With the RSD scale discomfort was rated on a 0–10 scale (0 = absence of discomfort & 10 = extremely uncomfortable) and reasons for discomfort ranked. Results: TC and RSD scales returned similar overall diurnal comfort change (0.4 ± 2.4 and 0.5 ± 2.0 units respectively). RSD data indicated that for both lenses the most common symptom at insertion was lens awareness but that this occurred 1.8 times more frequently for SiHy B than SiHy A (p = 0.001). This differential persisted during the wearing period but symptoms of dryness and tired eyes had increased their prominence for both lens types by the time of removal (p < 0.01). While tired eyes were reported roughly equally for both lenses, dryness was 1.4 times more common for SiHy A than SiHy B (p = 0.025). By the time of removal, pain was also reported 5 times more often with SiHy B than SiHy A (p = 0.034). Conclusions: Compared to the TC scale, RSD scaling produces additional information about the subjective experience of contact lens wearers that permits differentiation between contact lens types and time points. Dr Percy Lazon de la Jara is Head of Clinical Research at the Brien Holden Vision Institute and Visiting Fellow at the School of Optometry and Vision Science, University of New South Wales (UNSW), Sydney, Australia. He received his Optometry degree from Escuela
e19
Superior de Optica y Optometria and School of Optometry, Universidad Peruana Los Andes, Lima, Peru. He completed his PhD at the Cooperative Research Centre for Eye Research and Technology at UNSW, Sydney, in 2005. He has been admitted as a Fellow of the International Association of Contact Lens Educators and the American Academy of Optometry. http://dx.doi.org/10.1016/j.clae.2014.11.017 17 Fitting success of a new color silicone hydrogel contact lens in lotrafilcon b clear sphere wearers Jessie Lemp, Sharon Thomas Alcon Research Ltd., 6201 South Freeway, Fort Worth, TX 76134, USA Purpose: To determine whether clear, sphere lotrafilcon B contact wearers require a refit into color, sphere lotrafilcon B lenses. Method: A novel color SiHy lens (lotrafilcon B color, Alcon) was compared to a clear, sphere SiHy lens (lotrafilcon B; Alcon) in a randomized, parallel group, multisite study of existing lotrafilcon B contact lens wearers. Overall fit and centration were each graded on a 5-point scale. The proportion of subjects attaining same fit in both eyes was determined for both lotrafilcon B color and lotrafilcon B at Day 14 and Day 28. Same fit was defined as an eye that achieved an acceptable or optimal overall lens fit with the study lens that was also within one grade of the value observed on the same eye with the habitual lotrafilcon B lens. Results: Lotrafilcon B and lotrafilcon B color are comparable in terms of lens material, plasma surface treatment, blister pack solution, base curve (8.6 mm), diameter (14.2 mm), center thickness (0.08 mm at −3.00D), Dk/t (136 at −3.00D), water content (33%) and available powers (lotrafilcon B color includes plano power). The lotrafilcon B color lens incorporates 3 layers of ink encapsulated within the silicone material near the back surface of the lens. 251 subjects were evaluated in this study. Overall, 99.2% of subjects had the “same fit” at both visits with lotrafilcon B color lenses compared to habitual lenses; while 100% of subjects at Day 14 and 99.2% of subjects at Day 28 had the same fit with lotrafilcon B test lenses compared to habitual lenses. 99% of lotrafilcon B color lenses and 100% of lotrafilcon B lenses had acceptable centration at both visits. Conclusions: Lotrafilcon B and lotrafilcon B color are nearly identical in terms of technical attributes. Existing lotrafilcon B wearers do not require a refit to wear lotrafilcon B color lenses. Jessie Lemp is a Vision Care Brand Lead within the Global Medical Affairs department at Alcon where she oversees post-market research conducted on contact lenses and lens care products manufactured by Alcon. Jessie has a Masters Degree in Clinical Research and has worked in various roles at Alcon for the past 9 years. Jessie is planning to graduate in May 2014 with a doctorate in Biostatistics from the University of North Texas Health Science Center School of Public Health. http://dx.doi.org/10.1016/j.clae.2014.11.018